Highly Integrated Nano-Platform for Breaking the Barrier between Chemotherapy and Immunotherapy.
Fighting metastasis is a major challenge in cancer therapy, and stimulation of the immune system is of particular importance in the treatment of metastatic cancers. Here, an integrated theranostic nanoplatform was developed for the efficient treatment of highly metastatic tumors. Versatile functions including "And" logically controlled drug release, prolonged circulation time, tumor targeting, and anti-metastasis were integrated into doxorubicin (DOX) loaded, highly integrated mesoporous silica nanoparticles (DOX@HIMSNs) for a systemic treatment of highly metastatic triple negative breast cancer (TNBC). It was found that the good therapeutic effect of DOX@HIMSN was only partially attributed to its anticancer cytotoxicity. Most importantly, DOX@HIMSN could induce anticancer immune responses including dendritic cell (DC) maturation and antitumor cytokine release. Compared with the traditional tumor chemotherapy, the integrated theranostic nanoplatform we developed not only improved the tumor specific cytotoxicity but also stimulated antitumor immune responses during the treatment.
Key Laboratory of Biomedical Polymers of Ministry of Education, Institute for Advanced Studies (IAS), Department of Chemistry, Wuhan University , Wuhan 430072, P. R. China.|Hubei Collaborative Innovation Center for Advanced Organic Chemical Materials, Key Laboratory for the Green Preparation and Application of Functional Materials of Ministry of Education, Hubei University , Wuhan, Hubei 430062, P. R. China.
Di-Wei
DW
Zheng
Key Laboratory of Biomedical Polymers of Ministry of Education, Institute for Advanced Studies (IAS), Department of Chemistry, Wuhan University , Wuhan 430072, P. R. China.|Hubei Collaborative Innovation Center for Advanced Organic Chemical Materials, Key Laboratory for the Green Preparation and Application of Functional Materials of Ministry of Education, Hubei University , Wuhan, Hubei 430062, P. R. China.
Jia-Li
JL
Chen
Key Laboratory of Biomedical Polymers of Ministry of Education, Institute for Advanced Studies (IAS), Department of Chemistry, Wuhan University , Wuhan 430072, P. R. China.
Jing-Yi
JY
Zhu
Key Laboratory of Biomedical Polymers of Ministry of Education, Institute for Advanced Studies (IAS), Department of Chemistry, Wuhan University , Wuhan 430072, P. R. China.
Lei
L
Rong
Key Laboratory of Biomedical Polymers of Ministry of Education, Institute for Advanced Studies (IAS), Department of Chemistry, Wuhan University , Wuhan 430072, P. R. China.
Bin
B
Li
Key Laboratory of Biomedical Polymers of Ministry of Education, Institute for Advanced Studies (IAS), Department of Chemistry, Wuhan University , Wuhan 430072, P. R. China.
Qi
Q
Lei
Key Laboratory of Biomedical Polymers of Ministry of Education, Institute for Advanced Studies (IAS), Department of Chemistry, Wuhan University , Wuhan 430072, P. R. China.
Jin-Xuan
JX
Fan
Key Laboratory of Biomedical Polymers of Ministry of Education, Institute for Advanced Studies (IAS), Department of Chemistry, Wuhan University , Wuhan 430072, P. R. China.
Mei-Zhen
MZ
Zou
Hubei Collaborative Innovation Center for Advanced Organic Chemical Materials, Key Laboratory for the Green Preparation and Application of Functional Materials of Ministry of Education, Hubei University , Wuhan, Hubei 430062, P. R. China.
Cao
C
Li
Key Laboratory of Biomedical Polymers of Ministry of Education, Institute for Advanced Studies (IAS), Department of Chemistry, Wuhan University , Wuhan 430072, P. R. China.
Si-Xue
SX
Cheng
Hubei Collaborative Innovation Center for Advanced Organic Chemical Materials, Key Laboratory for the Green Preparation and Application of Functional Materials of Ministry of Education, Hubei University , Wuhan, Hubei 430062, P. R. China.
Zushun
Z
Xu
Key Laboratory of Biomedical Polymers of Ministry of Education, Institute for Advanced Studies (IAS), Department of Chemistry, Wuhan University , Wuhan 430072, P. R. China.
Xian-Zheng
XZ
Zhang
D045744:Cell Line, Tumor; D004317:Doxorubicin / Q000008:administration & dosage*; D006801:Humans; D007167:Immunotherapy; D053758:Nanoparticles; D012822:Silicon Dioxide; D000068936:Theranostic Nanomedicine
D012822:Silicon Dioxide; D004317:Doxorubicin
Theranostic platform; imaging; immune response; target; tumor therapy